Evaluation of Cardiovascular Risks Among the Participants of the ESC Congress 2025 (ESC-CVRISK2025)

May 26, 2026 updated by: European Society of Cardiology

Cross-Sectional Assessment of Cardiovascular Risk Among ESC Congress 2025 Participants

The European Society of Cardiology (ESC) is dedicated to promoting cardiovascular (CV) health and minimizing the occurrence of cardiovascular diseases throughout Europe. As a founding member of the European Alliance for Cardiovascular Health (EACH), the ESC is advocating for European and National Cardiovascular Health Plans which would include a cardiovascular and diabetes health check as part of a screening process for citizens. In line with this call for public health diagnosis of CV health, the ESC is committed to raising awareness on the need for actions and proposes to offer complimentary tests to delegates at ESC Congress 2025 in Madrid.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

1366

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Madrid, Spain
        • Evidenze Health España S.L.U.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

All adult attendees (including healthcare professional) attending the ESC Congress 2026 from August 29th to September 1st

Description

Inclusion Criteria:

  • All healthcare professionals (doctors, nurses, etc.) attending the ESC Congress 2025 from August 29th to September 1st
  • Subjects who declare that they are able to understand and give IC in English

Exclusion Criteria:

  • Subjects not willing to provide his/her consent to participate in the study.
  • Subjects who are not suitable candidates for blood extraction.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Systemic Coronary Risk Evaluation 2 (SCORE2) algorithm in patients without established CVD (primary prevention).
Time Frame: At baseline
At baseline
Second Manifestations or Arterial Disease (SMART) algorithm in patients with established CVD (secondary prevention)
Time Frame: At baseline
At baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

European Society of Cardiology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 29, 2025

Primary Completion (Actual)

September 1, 2025

Study Completion (Actual)

September 1, 2025

Study Registration Dates

First Submitted

May 19, 2026

First Submitted That Met QC Criteria

May 26, 2026

First Posted (Actual)

May 29, 2026

Study Record Updates

Last Update Posted (Actual)

May 29, 2026

Last Update Submitted That Met QC Criteria

May 26, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ESC-CVRISK2025

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Risk

Clinical Trials on blood draw

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe